Towards the end of Covid-19 testing reimbursements: a new chapter begins!

The Covid-19 pandemic has profoundly impacted societies worldwide, particularly in France where the healthcare system has mobilized tirelessly. Among the major measures, the introduction of free Covid-19 testing played a crucial role in the fight against the spread of the virus. However, in 2025, a significant turning point is emerging with the announced end of the general reimbursement of these tests by Health Insurance. This decision, driven by the evolution of the health context and WHO recommendations, raises many questions about its impact on individual practices, risk management, and the role of economic actors such as mutual insurance companies. Thus, despite the ongoing discreet circulation of the virus, France is implementing a major change in its testing strategy, favoring targeted management of at-risk populations while encouraging increased citizen responsibility. This new chapter also opens the way to a behavioral shift regarding testing, based on specific medical criteria and introducing a direct cost share for a broad majority of the population. This article examines in detail the modalities of this reform, its practical and economic implications, as well as the stakes for laboratories and major pharmaceutical players such as Sanofi, Roche, or bioMérieux involved in the manufacturing and distribution of tests. This transformation of the healthcare landscape is also an opportunity to analyze the changes in supplementary health devices and understand how mutual insurance companies are adapting to these evolutions to continue protecting policyholders in a post-pandemic France.

The current conditions for Covid-19 test reimbursement in France in 2025

Since March 2025, a significant reform has been applied regarding the reimbursement of Covid-19 tests. While, at the start of the health crisis in 2020, these tests were fully reimbursed by Health Insurance, the situation has evolved as the virus became less threatening according to scientific and institutional criteria. Indeed, the World Health Organization (WHO) removed Covid-19 from the list of health emergencies in May 2023. Nevertheless, the persistence of the virus in an endemic form requires continuous vigilance.

Now, only virological RT-PCR tests remain partially or fully reimbursed, and this exclusively for well-defined profiles. These profiles include:

• People at risk of severe forms due to a chronic condition or advanced age;
• Patients with a recognized long-term illness (ALD), such as cancer, diabetes, or respiratory failure;
• Immunocompromised individuals facing an increased risk of complications;
• Children and adolescents under 18;
• Senior citizens over 65, especially vulnerable to severe forms;
• Healthcare professionals and their employees, due to their constant exposure to the virus.

The reimbursement for these tests for so-called vulnerable persons varies between 60% and 100% depending on the case. Conversely, antigen tests and self-tests are no longer covered, except in very specific situations. This evolution marks the end of the era of systematic free testing, thus bringing a change in access behaviors to testing.

The decision to review the support framework is based, among other things, on an observation: Covid-19, although still present, no longer exerts intense pressure on hospitals. This observation is reinforced by reports from Santé publique France, which, in its epidemiological bulletin of March 26, 2025, states that suspicion suspension indicators remain low. Medical acts related to Covid-19 suspicion are thus few and stable across all age groups.

Type of test 🧪	Coverage by Health Insurance (%) ✅	Conditions for reimbursement 📋
RT-PCR Test	60 to 100%	Medical prescription + vulnerable profile
Antigen Test	0%	Not reimbursed except in exceptional cases
Self-test	0%	Not reimbursed

In light of these new rules, users are encouraged to approach testing more thoughtfully, in accordance with medical recommendations. Moreover, this transition has practical implications for laboratories and industrials involved in manufacturing and distributing tests, such as Roche, bioMérieux, Thermo Fisher Scientific, Abbott, or BD, which must adapt to fluctuating and segmented demand.

Furthermore, this change takes place in a context where Covid-19 vaccination remains encouraged, with still a partial reimbursement of 70% since March 1, 2025. This preventive aspect complements the new health policy, while keeping a dynamic approach to risk management active. Not to mention the supplementary devices, among which mutual insurance companies play a key role in reducing out-of-pocket expenses for individuals.

The impact of ending Covid-19 test reimbursement on mutual insurance companies and supplementary health insurances

The end of the general reimbursement by Health Insurance leads to a gradual transfer of costs to mutual insurance companies and supplementary health insurances. These play a crucial role in maintaining testing coverage, although their offers vary significantly depending on the contracts subscribed and the guarantees offered.

Prior to this reform, mutual insurance companies mainly covered the “co-payment” – the part not reimbursed by Health Insurance – ensuring almost full coverage for most insured persons. With the end of free antigen and self-tests, some insurers have decided to continue partial or full reimbursement under specific conditions. This aligns with an adaptation logic to the new health situation, while taking budget constraints into account.

Mutual companies offering premium plans are often better positioned to provide expanded Covid-19 test reimbursements, provided tests were prescribed by a health professional and that the Health Insurance has approved partial coverage for RT-PCR tests. For other contracts, coverage remains limited or nonexistent. This situation creates an uneven landscape that raises questions about access to care and the role of supplemental insurance in protecting vulnerable or socially disadvantaged populations.

• 🛡️ Responsible mutual insurance companies and obligations: at least two preventive acts reimbursed annually, including Covid-19 testing and vaccination.
• 💡 “Prevention” guarantee: sometimes allows partial reimbursement of tests in specific contracts.
• 📞 Advice: insured persons are recommended to contact their mutual insurance to understand the applicable reimbursement conditions.

This evolution of mutual insurance companies’ role is accompanied by a change in insured individuals’ behaviors. Some choose to opt for broader guarantees, while others remain cautious amid rising healthcare expenses. This realignment of the financial system of healthcare is part of a broader dynamic raising questions about the sustainability of public coverage and contributory solidarities.

Type of mutual insurance contract 📝	Covid-19 test coverage 🧪	Reimbursement conditions ✅
Premium contracts	Partial or full reimbursement	Test prescribed + partial coverage by Health Insurance
Standard contracts	Limited reimbursement	Often not covered except in specific cases
Responsible mutual insurance companies	At least two preventive acts reimbursed/year	Includes Covid-19 screening or vaccination

Finally, some mutual insurance companies are innovating by offering annual prevention packages that include tests and vaccination. This initiative, partly motivated by the desire to reduce the economic impact of infections, highlights the growing importance of supplementary health insurances in the overall management of the pandemic in a post-emergency context. Examples include specialized health entities like Laboratoires Pierre Fabre or Ipsen, which, although focusing on other therapeutic sectors, exemplify the increasing influence of a more integrated and coordinated healthcare industry.

Profiles of patients eligible for Covid-19 RT-PCR test reimbursement

The targeting of reimbursements is notably centered around individuals considered “at risk” of developing severe Covid-19. These profiles are essential for understanding the public health policies put in place and the criteria upon which the Health Insurance bases its decisions.

The list of affected patients is precise and based on a rigorous medical assessment. Among them are:

• Patients with long-term illnesses (ALD), which cover a broad spectrum of chronic conditions such as cancers, diabetes, respiratory failure, etc. These diseases can lead to increased vulnerability due to compromised immunity or significant organ fragility.
• Immunocompromised individuals, including those who have undergone organ transplants, are on chemotherapy, or are HIV-positive.
• Minors under 18, for whom health monitoring remains a priority, although the risk of severe forms is generally lower.
• Senior citizens over 65, due to their increased sensitivity to Covid-19 and the associated risk of severe complications, justifying closer monitoring.
• Health professionals, due to their more frequent exposure to the virus, including doctors, nurses, caregivers, and hospital staff.

This medical targeting has a tangible impact on individual and collective risk management. It relies on epidemiological data and scientific recommendations, such as those from Merck, Novartis, or Sanofi, which contribute to the development of tailored treatments and health measures for vulnerable individuals.

Within this context, presenting a medical prescription is an essential prerequisite for reimbursement. This process aims to limit inappropriate use and promote a rational management of available tests. It is also important to note that the role of pharmacies and laboratories, especially those of Roche and bioMérieux, is central in this organization, ensuring the quality and traceability of tests conducted.

Patient profile 👥	Criteria for coverage ✅	Health Insurance reimbursement 💶
Patients with ALD	Validated long-term illness	100%
Immunocompromised	Medical certificate	100%
Minors < 18 years	No additional criteria	100%
Individuals > 65 years	Vulnerable profile certified	100%
Health professionals	Employment proof	100%

Patients not matching these profiles will need to cover the costs of their RT-PCR tests as well as other antigen or self-tests. This change results in greater individual responsibility in health behaviors, while ensuring enhanced protection for the most vulnerable individuals.

Economic consequences for pharmaceutical laboratories and test manufacturers

Producers in the pharmaceutical and medical diagnostics sectors are experiencing direct repercussions from the modification of Covid-19 test reimbursements. Major players such as Sanofi, Roche, bioMérieux, Thermo Fisher Scientific, Abbott, and BD have invested heavily to meet the high demand for tests during the health crisis. The scheduled reduction in coverage leads to market contraction and necessitates strategic and industrial adaptation.

Over recent years, these companies have developed cutting-edge technologies to enhance the reliability, speed, and accessibility of tests. This ongoing innovation remains crucial given the persistence of the virus, especially through RT-PCR tests with high sensitivity and specificities tailored to variants.

Nevertheless, the decrease in reimbursements presents several challenges:

• 💸 Decrease in the number of tests conducted by the general population, reducing overall demand.
• ⚙️ Refocusing efforts on tests reserved for priority patients and specialized medical uses.
• 📉 Impact on the supply chain, from production to distribution in pharmacies and laboratories.
• 🔎 Increased need for investments in research to diversify offerings, including improved home testing solutions or ongoing monitoring.
• 🤝 Strengthened collaborations with health authorities to anticipate future needs and adjust commercial strategies.

For example, Roche and bioMérieux announced restructuring their test ranges, favoring products suitable for vulnerable populations identified. Thermo Fisher Scientific and Abbott have directed their research toward automated solutions enabling faster screening in laboratories. Meanwhile, Sanofi, Ipsen, Merck, and Novartis are involved in vaccination and complementary treatments, highlighting the synergy of approaches in combating Covid-19.

Company 💼	Economic impact 📊	Adaptation strategy ⚡
Sanofi	Focus on vaccination and treatment	Developing tailored vaccines
Roche	Restructuring test ranges	Targeting at-risk populations
bioMérieux	Reducing volume of consumer tests	Improving RT-PCR tests
Thermo Fisher Scientific	Automation of screening	More efficient laboratories
Abbott	Innovation in home testing	Fast and reliable tests
BD	Supply chain optimization	Stable procurement

This new phase underscores the necessity for corrective measures and coordinated actions to maintain the effectiveness of screening devices, while factoring in the economic realities of a sector in transformation. Additionally, considerations should also focus on sustainable resource management and preparedness for possible future viral resurgences.

The differences between RT-PCR, antigenic, and self-tests: reliability and reimbursement

The variety of tests used to detect Covid-19 offers a wide range of options. However, distinguishing these tests is essential to understanding current reimbursement criteria and health recommendations.

The RT-PCR test is recognized as the most reliable method. It relies on a nasal or saliva sample and detects the presence of viral RNA with high precision. However, this test is more expensive and requires equipped laboratories. Antigen tests provide rapid results in under 30 minutes by detecting viral proteins but are less reliable, especially among asymptomatic individuals or early in infection. Finally, self-tests, sold in pharmacies or mass retailers, offer an accessible solution without prescription, though they are the least reliable.

• 🔬 RT-PCR: high sensitivity and specificity, covered under conditions.
• ⏱️ Antigen tests: quick but less reliable, not reimbursed except in rare cases.
• 🏠 Self-tests: accessible and practical, without reimbursement.

The March 2025 reform reflects this hierarchy by excluding antigenic and self-tests from standard reimbursement, thus emphasizing an economic optimization and focus on actual medical needs.

In this context, laboratories such as Roche or bioMérieux concentrate their efforts on continuously improving RT-PCR test reliability. Recent studies highlight the importance of accurate diagnosis to better guide treatments and limit virus spread.

Type of test 🧬	Reliability 📈	Result time ⏳	Reimbursement by Health Insurance 💶
RT-PCR	High	24-48 hours	60-100%
Antigen test	Moderate to low	15-30 minutes	0%
Self-test	Low	15-20 minutes	0%

This distinction between tests also serves an educational purpose by encouraging users to favor validated medical procedures based on prescriptions and proper follow-up, thereby reducing errors and false negatives.

New health challenges associated with the non-reimbursement of Covid-19 tests

The end of the widespread reimbursement of Covid-19 tests raises major public health and healthcare organization issues. By limiting coverage to only at-risk profiles, the French system relies on targeted risk management while calling for greater citizen engagement in health monitoring.

Among the identified challenges is maintaining rapid detection of symptomatic cases, essential to preventing transmission chains. The absence of free testing reimbursement for the general public could alter behaviors, with a potential risk of underdiagnosis, especially among youth or asymptomatic individuals.

• 🚨 Increased risk of silent virus spread among untested populations.
• 🏥 Need to reinforce communication regarding risks and protective measures.
• 👥 Ongoing reminder to exercise caution, especially during winter months.
• 📊 More complex epidemiological surveillance, requiring new digital tools.
• 🔄 Adjustment of hospital capacities to fluctuations in severe cases.

To address these challenges, health authorities recommend a policy of prescribed testing, combined with measures such as vaccination, mask-wearing in high-risk situations, and promoting better hygiene practices. This strategy aims to balance health effectiveness and budget control.

It is worth noting that free or reimbursed masks, such as surgical masks or FFP2, are maintained for vulnerable or immunocompromised individuals. They must justify their situation with an official document confirming their need. This targeted support reflects a delicate balance between proactive prevention and resource rationalization.

Health challenge ⚕️	Description 📝	Recommended solution 💡
Inadequate screening	Fewer tests conducted by the general public	Promotion of prescribed and targeted screening
Silent spread	Risk of undetected asymptomatic cases	Maintaining barrier gestures and encouraging vaccination
Variable hospital burden	Need for resource adaptation	Enhanced epidemiological monitoring

Ultimately, this adjustment fits within a broader post-pandemic health transition framework, aiming to find sustainable balances between prevention, resilience, and social acceptability.

Healthcare professionals’ adaptation to the new Covid-19 testing organization

The change in reimbursement policy significantly impacts healthcare professionals, both in their medical roles and their economic involvement. Pharmacists, general practitioners, and analysis laboratories now need to adjust their practices to align with the new guidelines.

For physicians, prescribing an RT-PCR test becomes a crucial step for reimbursement access. This involves careful evaluation of patients based on vulnerability criteria, avoiding overload with unjustified tests. The role of prescriptions is thus reinforced as a tool for health control.

Pharmacists must support patients through this transition by informing them about reimbursement possibilities and limitations, as well as alternative options offered by mutual insurers. They also play a role in raising awareness about protective measures and the importance of regular vaccination. Stock management of tests is evolving, with a probable reduction in free self-test distribution.

• 📋 In-depth review of patient files and prescription criteria by physicians.
• 💬 Clear and precise information from pharmacists about reimbursement procedures.
• ⚖️ Adapted stock management and anticipation of needs by laboratories.
• 🤝 Strengthened interprofessional collaboration to ensure a coherent care pathway.
• 🛡️ Support for vulnerable populations through personalized assistance.

This new organization also encourages integrating digital tools into screening follow-up, with dedicated platforms for declaration, prescription traceability, and coverage rate assessment.

Healthcare professional 👩‍⚕️	Role in the new organization 🔄	Main challenges 🎯
Doctors	Strict prescription of RT-PCR tests	Medical oversight and resource management
Pharmacists	Advising and guiding patients	Information dissemination and awareness
Laboratories	Analysis management and stock control	Diagnostic reliability and range renewal

Ultimately, enhanced interprofessional coordination and communication appear as essential levers to manage this intermediate phase of health transition.

Changing social and behavioral habits related to Covid-19 screening

The end of widespread reimbursement also signals a profound change in testing behaviors. During the health crisis, testing was widespread and almost systematic at the emergence of symptoms. This strategy was based on mass screening policies, enabling rapid control of viral spread.

Since the new rules were implemented, people not considered at risk now need to self-fund their tests. This economic factor significantly modifies the frequency and intensity of testing behaviors. Several sociologists and public health specialists highlight a growing “selectivity” phenomenon in access to testing:

• 💰 Tests are now perceived as a specific expense, encouraging rational use.
• 🔍 Individuals increasingly prefer self-monitoring symptoms before resorting to testing.
• 👨‍👩‍👧‍👦 Households with at-risk persons maintain a high level of vigilance.
• 📉 A general decline in testing, especially among young people and active individuals without severe symptoms.
• ⚠️ The risk, pointed out as a concern, of underestimating actual viral circulation.

This context urges reconsideration of awareness campaigns and strengthening messages promoting collective prevention, emphasizing social responsibility and solidarity toward the most vulnerable.

Social behavior 🧍‍♂️	Consequence 📉	Recommended measures 💬
Reduction of testing among non-vulnerable individuals	Less detection of asymptomatic cases	Promotion of prescribed and targeted testing
Increase in self-monitoring	Delay in detection	Self-assessment digital interfaces
Maintaining vigilance in families	Enhanced protection for vulnerable groups	Precise and sustained information

Future outlook for post-Covid health management and the role of medical innovations

The discontinuation of the general reimbursement of Covid-19 tests marks a phase of “normalization” in post-pandemic management. This stage offers an opportunity to incorporate new knowledge to better anticipate future crises and develop more resilient and targeted systems.

Technological and medical innovations play a key role in this transformation. Companies such as Sanofi, Roche, bioMérieux, Thermo Fisher Scientific, and Abbott are investing in the development of more precise, easily deployable tests that enable dynamic monitoring of virus evolution and variants. This orientation aims to support sustainable surveillance without draining public financial resources.

• 🧬 Development of multiplexed tests capable of detecting multiple viruses simultaneously, facilitating differentiation between flu and Covid-19.
• 🤖 Integration of artificial intelligence to improve result analysis and epidemic trend prediction.
• 📱 Creation of secure mobile applications for individual test monitoring and contact case notifications.
• 💉 Ongoing improvement of vaccines and treatments through coordinated international collaborations.
• 🌍 Implementation of global health alert systems for rapid and effective responses.

Moreover, the medicalization of testing is driving the emergence of personalized care pathways, combining prevention, diagnosis, and treatment. This aspect is supported by pharmaceutical and biotechnological laboratories like Novartis, Ipsen, and Merck, which explore innovative avenues to enhance patient resilience and reduce the severity of Covid-19 forms.

Medical innovation 🚀	Objective 🎯	Expected impact 💡
Multiplexed tests	Differential diagnosis of flu and Covid	Reducing errors and delays
AI in epidemic analysis	Forecasting and control	Better crisis management
Mobile applications	Personalized monitoring	Enhanced reactivity and safety

FAQ on the end of Covid-19 test reimbursement

• ❓ Who can still benefit from Covid-19 RT-PCR test reimbursement?

  People with long-term illnesses, immunodeficiencies, minors under 18, vulnerable seniors, and healthcare professionals can still receive partial or full reimbursement upon presenting a prescription.

• ❓ Are self-tests and antigen tests reimbursed?

  Since March 2025, these tests are no longer reimbursed by Health Insurance except in rare exceptions. They must be directly covered by patients or their mutual insurers depending on the contracts.

• ❓ How do I find out if my mutual insurance reimburses Covid-19 tests?

  It is important to contact your mutual insurer directly to know the specific procedures, especially for premium contracts offering guarantees related to screening and prevention.

• ❓ What are the most reliable Covid-19 tests?

  The RT-PCR test is the most reliable. It accurately detects the presence of the virus, unlike antigenic or self-tests which are less reliable.

• ❓ What is the main reason behind the end of systematic reimbursement?

  This decision stems from the fact that Covid-19 is no longer a health emergency according to the WHO, with low and stable virus circulation, justifying targeted rather than systematized coverage.

Source: ymanci.fr